Prospective machine-learning screen identifies six previously unreported OATP1B1 inhibitors
Researchers trained and compared seven machine-learning classifiers for OATP1B1 transporter inhibition. In prospective CHO-cell testing, 15 of 19 compounds predicted active by SVC models inhibited the transporter; six (abamectin, asiaticoside, berbamine, doramectin, mobocertinib and umbralisib) were described as previously unreported OATP1B1 inhibitors.
Technology: Seven molecular-fingerprint machine-learning classifiers, with prospective selection by support vector classifier (SVC)
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: In prospective CHO-cell testing, 15 of 19 compounds predicted active by SVC models inhibited the transporter; six (abamectin, asiaticoside, berbamine, doramectin, mobocertinib and umbralisib) were described as previously unreported OATP1B1 inhibitors. The new candidate screen used contracted Eurofins assays; external execution is not a separate replication study.
- Still unknown: The 84% refers to a small prospective test set of 19 compounds, and transporter inhibition was measured in vitro in engineered CHO cells. These findings flag possible drug–drug interaction liability; they do not show clinical interaction or patient outcome. The authors qualify six inhibitors as appearing novel at publication.
- AI role: Models trained on in-vitro OATP1B1 inhibition data ranked compounds for prospective testing. Researchers tested 19 model-selected compounds in transporter-expressing CHO cells and observed inhibition for 15, including six compounds the authors described as novel OATP1B1 inhibitors.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC9873312/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: at percentile 89 of works of the same type, year and subfield (OpenAlex work metrics, 31 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.